Navigation Links
Pfizer joins open-access medicinal chemistry public-private collaboration
Date:6/10/2010

The Structural Genomics Consortium (SGC) and Pfizer today announced that Pfizer will join the SGC-led public-private collaboration to generate small molecule inhibitors "chemical probes" for proteins involved in epigenetic signalling.

Pfizer and GlaxoSmithKline (GSK) are now members of this collaboration, launched in late 2008 with the aim to provide the community with high quality research reagents, free from restriction on use.

Globally the collaboration includes the three SGC laboratories in Oxford, Toronto and Stockholm, the National Institutes of Health Chemical Genomics Center in Bethesda, the Departments of Chemistry and Biochemistry at the University of Oxford, the Department of Chemistry at Ume University and a number of additional collaborators in academia. The program has been awarded a total of US $15M in grant support from the Wellcome Trust, the Ontario Ministry of Research and Innovation in Canada and the Swedish Foundation for Strategic Research to support activities in the UK, Canada and Sweden, respectively.

The collaboration aims to develop small molecules that can stimulate or block the activity of proteins involved in epigenetic control. The study of epigenetics addresses heritable changes in gene function that occur without a change in the DNA sequence. Alterations in these processes are linked to many common diseases, and there is a strong belief that a better understanding of epigenetics could eventually lead to treatments for diseases such as cancer, diabetes, obesity and many psychiatric diseases. Epigenetics is an area of biology that is poorly understood and the availability of chemical probes should dramatically increase our understanding; some of these probes may also be starting points for drug discovery.

Pfizer is joining the program after having formalized an agreement with the University of Oxford, SGC and GSK. Pfizer will, like GSK, provide medicinal chemistry support to the project. The collaboration is special in that it brings the medicinal chemistry expertise within industry together with the biological expertise within academia to address an emerging area of biology. The ability to add extra industrial members further demonstrates this consortium as a potential working model for pre-competitive interactions between academia and industry within the field of medicinal chemistry.

In keeping with SGC policy, the structure and function of each probe will be made freely available.

Dr Tony Wood, Vice President and Heads of Worldwide Medicinal Chemistry at Pfizer, said: "This collaboration exemplifies our thinking with respect to public-private collaboration that facilitate 'blue sky' research between industry and academia. It is hoped that combining forces in this way will lead to the rapid development and deployment of research tools. This should help us understand the role that this important group of gene families play in human disease and should aid the overarching goal of providing effective medicines to patients."

Dr Aled Edwards, the SGC Chief Executive, adds: "The problem we are tackling together is too big for any single laboratory or organization. We are thrilled that to have two leaders in pharmaceutical research and medicinal chemistry in this global project, and are delighted at this opportunity to collaborate with some of the top medicinal chemists in the world."


'/>"/>

Contact: Johan Weigelt
johan.weigelt@ki.se
46-702-630-255
Wellcome Trust
Source:Eurekalert

Related medicine news :

1. AUDIO from Medialink and Pfizer: Glaucoma - The Sneak Thief of Sight
2. Sigma-Aldrich Reaches Agreement to Sell Pfizers Bioactive Small Molecule Compounds
3. VIDEO from Medialink and National Fibromyalgia Association and Pfizer Inc.: The Science Behind Fibromyalgia
4. Luckey & Mullins Joins with Other National Construction Defect Law Firms to Form Chinese Drywall Legal Network
5. The Chicago Office of McDonald Hopkins Continues to Expand: Healthcare Attorney, Charles F. MacKelvie, Joins the Firms National Healthcare and Healthcare Restructuring Practice Groups
6. Mary Kay Thalken Joins StatCom as Enterprise VP, Western Region
7. CallSource joins Starkey Hearing Foundation to Tackle Children's Hearing Loss in Super Bowl Mission
8. Robert Naticchia Joins CONNEXION Healthcare as Executive Vice President, Client Services
9. Industry Advisor Joins OrthoAccel Technologies, Inc.
10. Worlds #1 Health Brand for Kids Joins Forces With Worlds #1 In-School Childrens Theatre
11. Oncology Industry Veteran, Joe Baffone, Joins onPoint Oncology, LLC.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
Breaking Medicine Technology: